Premium
Levamisole as adjuvant immunotherapy in breast cancer
Author(s) -
TreurnietDonker Annette D.,
MeischkeDe Jongh Marlies L.,
Van Putten Wim L. J.
Publication year - 1987
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19870501)59:9<1590::aid-cncr2820590911>3.0.co;2-r
Subject(s) - levamisole , medicine , placebo , adjuvant , discontinuation , breast cancer , immunotherapy , cancer , oncology , drug , randomized controlled trial , radiation therapy , surgery , pharmacology , pathology , alternative medicine
Results are reported of a double‐blind randomized study on 198 patients with resectable node positive mammary cancer, evaluating the effect of the immune modulating drug levamisole in an adjuvant setting. Drug treatment was started after completion of postoperative radiotherapy. In a two‐arm trial 97 patients used levamisole and 101 patients used a placebo. No difference was noted in overall survival and disase‐free survival between the two groups. Toxicity was reason for discontinuation of the drug in 30 of 97 of the patients in the levamisole group and 8/101 in the placebo group.